Engineers Gate Manager’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Engineers Gate Manager’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-18,500	Closed	-$154K	–	2463
2021 Q4	$154K	Buy	+18,500	New	+$152K	0.01%	1725
2021 Q3	–	Sell	-24,500	Closed	-$167K	–	2085
2021 Q2	$167K	Buy	+24,500	New	+$204K	0.01%	1442
2021 Q1	–	Sell	-14,300	Closed	-$100K	–	2204
2020 Q4	$100K	Buy	+14,300	New	+$111K	﹤0.01%	1587
2020 Q1	–	Sell	-17,500	Closed	-$153K	–	2039
2019 Q4	$153K	Buy	+17,500	New	+$94.6K	0.01%	1511

Other funds holding JNCE

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Engineers Gate Manager's JNCE Position: Q1 2022 in Review

Engineers Gate Manager sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2022, closing a stake of 18,500 shares — an estimated $154K sold.

Engineers Gate Manager first reported a position in JNCE in Q4 2019 and held it in 4 quarters. The position peaked at $167K in Q2 2021. 113 funds tracked by Wall St. Rank hold JNCE as of Q1 2022.

Engineers Gate Manager reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Engineers Gate Manager sold 18,500 Jounce Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $154K.
Engineers Gate Manager first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2019 and held it in 4 quarters.
Engineers Gate Manager's Jounce Therapeutics, Inc. Common Stock position peaked at $167K in Q2 2021.
113 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Engineers Gate Manager's 13F filing for Q1 2022, filed 16 May 2022.